Dose-finding study of AJG533 in patients with chronic constipation (Phase 2 study)

Trial Profile

Dose-finding study of AJG533 in patients with chronic constipation (Phase 2 study)

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Elobixibat (Primary)
  • Indications Constipation
  • Focus Therapeutic Use
  • Sponsors Ajinomoto Pharma
  • Most Recent Events

    • 09 May 2017 Primary endpoint "Frequency of Spontaneous Bowel Movement" has been met as per results published in the Digestive Disease Week 2017.
    • 09 May 2017 Results presented at the Digestive Disease Week 2017
    • 27 Apr 2017 Results from this trial will be presented at Digestive Disease Week (DDW) 2017, according to an Albireo Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top